Contract facts
NONENo full NAICS 325412 intel page yet. Browse NAICS intelligence
PLUVICTO AND LUTATHERA INJECTION is a federal NONE award for Defense Health Agency Hcd West held by Novartis Pharmaceuticals Corp. Estimated value $206K ($206K obligated). Current period of performance ends Sep 30, 2026. Last award drew 1 bidder. Place of performance: EAST HANOVER NJ.
Recompete timing
PublicCurrent PoP ends Sep 30, 2026 (40 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.
Incumbent footprint
Public recordNovartis Pharmaceuticals Corp — $23.5M obligated across 59 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract HT941026FE027?
HT941026FE027 (Pluvicto and lutathera injection) is a Defense Health Agency Hcd West award with a potential value of $206K, currently held by Novartis Pharmaceuticals Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
Which office awarded HT941026FE027?
Defense Health Agency Hcd West awarded HT941026FE027 to Novartis Pharmaceuticals Corp (potential $206K).
Who is the incumbent on HT941026FE027?
Novartis Pharmaceuticals Corp is the incumbent with $23.5M across 59 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2026.
When does Novartis Pharmaceuticals Corp’s HT941026FE027 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 30, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.